Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts

Clicks: 1
ID: 319130
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #515 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.
Reference Key
openalex_W7166547721 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Matthew Spinelli, Megan J. Heise, David V. Glidden, Janet Grochowski, Jon Oskarsson, Larisa Niles-Carnes, Eudiah Ochieng, Meredith Lora, Amalia Aldredge, Nathanael Gistand, Chesa Cox, Jonathan Colasanti, Monica Gandhi, Lauren F. Collins
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag392
URL
https://doi.org/10.1093/cid/ciag392
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.